Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Product Progress and Commercial Growth Put Halma plc (LSE:HLMA) in Focus

Halma plc (LSE:HLMA) is assessed against its Main Market market context and its core business in safety, environmental and health technology businesses.

Ankur Sharma | 20 October 2026

Healthcare spotlight: what could move NIOX Group plc (LSE:NIOX) as London Stock Exchange AIM market investors look ahead

NIOX Group plc (LSE:NIOX) is being assessed through the lens of its healthcare exposure and its ability to turn strategic plans into measurable operating performance.

Ankur Sharma | 20 October 2026

Oxford Nanopore Takes a Breather After a Blistering Rebound: Is the Sequencing Story Back on Track?

The modest decline follows a dramatic recovery in the shares. Oxford Nanopore closed at around 122p on 18 August, the day before its interim results, and has since rallied by roughly 70%. Some profit-taking after such a strong move is not surprising.

Divya Sood | 20 October 2026

IXICO PLC (LSE:IXI) Revenue Outlook Upgrade Supports Neuroimaging Momentum

IXICO raised its expected annual revenue after analysis orders accelerated towards the end of its financial year. Expected revenue exceeded the guidance already increased during the summer. The year-end order book grew, and the expected adjusted operating loss improved relative to market expectations despite …

Ankur Sharma | 20 October 2026

ImmuPharma PLC (LSE:IMM) Pipeline Progress Keeps Autoimmune and Diabetes Potential in Focus

The September interim update described continued development of P140 and Kapiglucagon following the earlier fundraising. P140 remains a prospective autoimmune licensing asset, with a companion-diagnostic approach intended to improve patient selection. Kapiglucagon development includes specialist manufacturing and bioanalytical work. These are separate programmes with …

Ankur Sharma | 20 October 2026

Product Progress and Commercial Growth Put RUA Life Sciences Plc (LSE:RUA) in Focus

RUA Life Sciences Plc (LSE:RUA) is assessed against its AIM market context and its core business in medical-device technologies and biomaterials development.

Ankur Sharma | 20 October 2026

Product Progress and Commercial Growth Put Tristel plc (LSE:TSTL) in Focus

Tristel plc (LSE:TSTL) is assessed against its AIM market context and its core business in infection-prevention products for medical devices and healthcare surfaces.

Ankur Sharma | 20 October 2026

ImmuPharma plc (LSE:IMM) Draws London Market Attention: What Is Driving the Focus and What Comes Next?

The immediate question for holders of ImmuPharma plc (LSE:IMM) is whether renewed trading interest reflects durable improvements in fundamentals or a short-lived change in positioning. Share-price gains can arise from earnings releases, operational announcements, investor flows or thin liquidity. These explanations should not be …

Ankur Sharma | 20 October 2026

Ondine Biomedical, Inc. (LSE:OBI) Draws London Market Attention: What Is Driving the Focus and What Comes Next?

The immediate question for holders of Ondine Biomedical, Inc. (LSE:OBI) is whether renewed trading interest reflects durable improvements in fundamentals or a short-lived change in positioning. Share-price gains can arise from earnings releases, operational announcements, investor flows or thin liquidity. These explanations should not …

Ankur Sharma | 20 October 2026

Bioventix Plc (LSE:BVXP) Draws London Market Attention: What Is Driving the Focus and What Comes Next?

The immediate question for holders of Bioventix Plc (LSE:BVXP) is whether renewed trading interest reflects durable improvements in fundamentals or a short-lived change in positioning. Share-price gains can arise from earnings releases, operational announcements, investor flows or thin liquidity. These explanations should not be …

Ankur Sharma | 20 October 2026
Support

Hi! How can we help you today?

Loading…